Jazz Pharmaceuticals PLC (JAZZ) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

Total Cash From Operating Activities Chart for Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ) operating cash flow for FY2025 was USD 1.4B, a -2.9% change from FY2024. Jazz Pharmaceuticals PLC's operating cash flow moved from USD -52.2M in 2005 to USD 1.4B in 2025 over 20 years. Operating cash flow compound annual growth rate: 5-year CAGR of 8.5%, 10-year CAGR of 9.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$15.02B
Implied Share Price
$231.39
Enterprise Value
$17.47B
Revenue (TTM)
$4.60B
EBITDA
$1.93B
Profit Margin
20.45%
Trailing P/E
16.18
Forward P/E
10.89
Price/Book (MRQ)
3.25
Price/Sales (TTM)
3.26
EV/EBITDA
11.03
EV/Revenue
3.88
Dividend Yield
—
Book Value
$74.10
Free Cash Flow (FY2025)
$1.15B
Free Cash Flow Yield
7.63%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.